Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Space radiation and microgravity as models of accelerated aging: modulation of hepatic miRNA-TGF-β networks associated with senescence and fibrosis.

GeroScience·2026
Same author

Ovarian-derived signals reprogram hepatic lipid metabolism in aging: Implications for therapeutic targeting of metabolic dysfunction.

Advances in translational research·2026
Same author

Multi-Omics Characterization of Human Molecular Responses to Spaceflight Across Two Independent Missions.

bioRxiv : the preprint server for biology·2026
Same author

Impact of miR-181a-5p and miR-1249-3p treatment on the visceral adipose tissue transcriptome of female mice.

GeroScience·2026
Same author

Modulatory role of blackberry fruit standardized extract on brain redox status and insulin signaling in type 2 diabetic rats.

Molecular biology reports·2026
Same author

Active immunization against myostatin and activin A improves skeletal muscle performance in growth hormone-deficient mice.

GeroScience·2026

Related Experiment Video

Updated: Jul 22, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

101.8K

Senolytics prevent age-associated changes in female mice brain.

Olivia Wyse Faria1, Mayara Sandrielly Soares de Aguiar2, Julia Eisenhardt de Mello2

  • 1Programa de Pós-Graduação em Bioquímica e Bioprospecção, Laboratório de Biomarcadores, Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitário S/N, Pelotas, RS, Brazil.

Neuroscience Letters
|March 14, 2024
PubMed
Summary

The combination of dasatinib and quercetin (D + Q) protects the aging female brain from oxidative stress and neurochemical changes. This neuroprotective effect may help prevent age-related cognitive decline and Alzheimer's disease susceptibility.

Keywords:
AcetylcholinesteraseBrainDasatinibNa(+), K(+)-ATPaseQuercetinRedox status

More Related Videos

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
14:57

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

94.1K
A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration
08:17

A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration

Published on: February 27, 2018

16.4K

Related Experiment Videos

Last Updated: Jul 22, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

101.8K
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
14:57

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

94.1K
A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration
08:17

A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration

Published on: February 27, 2018

16.4K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Aging Research

Background:

  • Female aging involves hormonal decline, increasing Alzheimer's disease susceptibility.
  • Dasatinib and quercetin (D + Q) combination shows potential neuroprotective effects.
  • Age-related changes in the brain include oxidative stress and altered enzyme activities.

Purpose of the Study:

  • To evaluate the neuroprotective effects of D + Q in aging female mice.
  • To assess the impact of D + Q on inflammatory and oxidative stress markers.
  • To investigate the influence of D + Q on acetylcholinesterase and Na+, K+-ATPase activities in the female brain.

Main Methods:

  • Female C57BL/6 mice were divided into control and D + Q treatment groups.
  • Treatment involved oral gavage of D (5 mg/kg) + Q (50 mg/kg) every two weeks from 30 days of age.
  • Animals were euthanized at 6 and 14 months of age for brain analysis.

Main Results:

  • Control mice showed increased reactive species, lipid peroxidation, and reduced antioxidant enzyme activity with age.
  • D + Q treatment counteracted age-associated increases in reactive species and protected catalase activity.
  • D + Q prevented the age-related reduction in Na+, K+-ATPase activity and increased acetylcholinesterase activity.

Conclusions:

  • D + Q demonstrates significant neuroprotection against age-associated neurochemical alterations in female mice.
  • The findings suggest D + Q as a potential therapeutic strategy for age-related neurological decline in females.
  • Further research is warranted to explore D + Q's efficacy in preventing Alzheimer's disease.